French biopharma firm Innate Pharma reports Q1 2024 financial results and updates strategy, emphasizing progress in drug pipeline.
Innate Pharma, a French biopharmaceutical company, reported its Q1 2024 financial results and business update. The company is focusing on executing its strategy with partnered drug candidates while advancing its proprietary second generation ANKL medicines. CEO ad interim, Hervé Brailly, highlighted the ongoing progress in their pipeline of drugs. Financial details were not specified in the summary.
May 14, 2024
4 Articles